Literature DB >> 21290094

[Quality of life after prostate cancer in members of support groups: first results of the HAROW retro study].

B Bestmann1, T Kollakowski, L Weissbach.   

Abstract

BACKGROUND: The HAROW project was founded by the Stiftung Männergesundheit to have a closer look at the situation of patients who suffer from prostate cancer, especially focusing on their situation regarding supply and services.
METHODS: In the current study 504 members of support groups were asked about their health-related quality of life (QOL). Standardized questionnaires were used to ensure the validation. Both the diagnosis and initial therapy dated back at least 12 months. The EORTC QLQ-C30 as well as the prostate-specific module (PSM) were used as questionnaires.
RESULTS: Various forms of therapies proved to have different impacts on QOL. Patients with a combined hormonal therapy and radiation therapy evaluated their QOL worse than others with different forms of therapies. Patients with cured tumors reported significantly better data than those in the middle of therapy or the uncured.
CONCLUSION: The data even indicate that their QOL is similar to people living under normal circumstances and health situations. Particular characteristics however exist on specific scales. Patients attending support groups show surprisingly high values for QOL.

Entities:  

Mesh:

Year:  2011        PMID: 21290094     DOI: 10.1007/s00120-010-2491-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  10 in total

1.  The challenge of response shift for quality-of-life-based clinical oncology research.

Authors:  M A Sprangers; C E Schwartz
Journal:  Ann Oncol       Date:  1999-07       Impact factor: 32.976

Review 2.  Quality of life following treatment for early prostate cancer: does low dose rate (LDR) brachytherapy offer a better outcome? A review.

Authors:  Alastair Henderson; Robert W Laing; Stephen E M Langley
Journal:  Eur Urol       Date:  2004-02       Impact factor: 20.096

3.  Validation of the German prostate-specific module.

Authors:  Beate Bestmann; Volker Rohde; Jens-Ulrich Siebmann; Razvan Galalae; Wolfgang Weidner; Thomas Küchler
Journal:  World J Urol       Date:  2006-01-19       Impact factor: 4.226

4.  Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.

Authors:  Montserrat Ferrer; José Francisco Suárez; Ferran Guedea; Pablo Fernández; Víctor Macías; Alfonso Mariño; Asunción Hervas; Ismael Herruzo; María José Ortiz; Humberto Villavicencio; Jordi Craven-Bratle; Olatz Garin; Ferran Aguiló
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-05       Impact factor: 7.038

5.  Interpreting the significance of changes in health-related quality-of-life scores.

Authors:  D Osoba; G Rodrigues; J Myles; B Zee; J Pater
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

6.  Prostate-specific symptoms of prostate cancer in a German general population.

Authors:  B Bestmann; C Loetters; T Diemer; W Weidner; T Küchler; V Rohde
Journal:  Prostate Cancer Prostatic Dis       Date:  2006-11-14       Impact factor: 5.554

7.  Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association.

Authors:  R G Middleton; I M Thompson; M S Austenfeld; W H Cooner; R J Correa; R P Gibbons; H C Miller; J E Oesterling; M I Resnick; S R Smalley
Journal:  J Urol       Date:  1995-12       Impact factor: 7.450

8.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

9.  Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.

Authors:  John L Gore; Lorna Kwan; Steve P Lee; Robert E Reiter; Mark S Litwin
Journal:  J Natl Cancer Inst       Date:  2009-06-09       Impact factor: 13.506

10.  An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer.

Authors:  George van Andel; Andrew Bottomley; Sophie D Fosså; Fabio Efficace; Corneel Coens; Stephane Guerif; Howard Kynaston; Paolo Gontero; George Thalmann; Atif Akdas; Sven D'Haese; Neil K Aaronson
Journal:  Eur J Cancer       Date:  2008-09-05       Impact factor: 9.162

  10 in total
  3 in total

Review 1.  [An essay on health services research-contributions from urology].

Authors:  P J Goebell
Journal:  Urologe A       Date:  2018-08       Impact factor: 0.639

2.  [Prostate cancer in routine healthcare: health-related quality of life after inpatient treatment].

Authors:  S Henninger; S Neusser; C Lorenz; E M Bitzer
Journal:  Urologe A       Date:  2014-12       Impact factor: 0.639

3.  [PSA screening 2013: background and perspectives].

Authors:  F Recker; D Seiler; B Seifert; M Randazzo; M Kwiatkowski
Journal:  Urologe A       Date:  2014-06       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.